3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
3137
Triple Negative Breast Neoplasms
514
Ovarian Neoplasms
230
Colorectal Neoplasms
190
Carcinoma, Non-Small-Cell Lung
189
Prostatic Neoplasms
184
Neoplasms
176
Neoplasm Metastasis
164
Lung Neoplasms
164
Melanoma
118
Stomach Neoplasms
114
Pancreatic Neoplasms
113
Endometrial Neoplasms
107
Uterine Cervical Neoplasms
95
Squamous Cell Carcinoma of Head and Neck
88
Colonic Neoplasms
82
Carcinoma, Intraductal, Noninfiltrating
82
Head and Neck Neoplasms
81
Sarcoma
62
Breast Carcinoma In Situ
62
Carcinoma, Renal Cell
61
Urinary Bladder Neoplasms
60
Motor Activity
59
Esophageal Neoplasms
58
Brain Neoplasms
50
Lymphedema
44
Breast Cancer Female
41
Liver Neoplasms
39
Advanced Breast Cancer
39
HER2-positive Breast Cancer
38
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Breast
×
1 year
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled